1. Metabolic Enzyme/Protease
  2. Phosphodiesterase (PDE)

PF-04447943 (Synonyms: PF 04447943; PF04447943)

Cat. No.: HY-15441
Handling Instructions

PF-04447943 is a potent inhibitor of human recombinant PDE9A (IC50=12 nM) with >78-fold selectivity, respectively, over other PDE family members (IC50>1000 nM).

For research use only. We do not sell to patients.
PF-04447943 Chemical Structure

PF-04447943 Chemical Structure

CAS No. : 1082744-20-4

Size Price Stock Quantity
Free sample   Apply now  
10 mM * 1 mL in DMSO $275 In-stock
5 mg $250 In-stock
10 mg $450 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

Top Publications Citing Use of Products
  • Biological Activity

  • Protocol

  • Technical Information

  • References

Description

PF-04447943 is a potent inhibitor of human recombinant PDE9A (IC50=12 nM) with >78-fold selectivity, respectively, over other PDE family members (IC50>1000 nM).

IC50 & Target

IC50: 12 nM (PDE9A)[1]

In Vitro

Using recombinant human, rhesus, and rat PDE9A2 in a cell free assay PF-04447943 is shown to have a Ki of 2.8±0.26, 4.5±0.13, and 18.1±1.9 nM (n=4, 11 and 9 respectively). PF-04447943 is found to be highly selective over other PDE enzymes (PDE1, Ki=8600±2121 nM, n = 5; PDE2A3, Ki>99,000 nM; PDE3A, Ki>50,000 nM; PDE4A, Ki>29,000 nM; PDE5A, Ki=14,980±5025 nM, n=5; PDE6C, Ki=5324±2612 nM, n=4; PDE7A2, Ki>75,000 nM; PDE8A, Ki>50,000 nM; PDE10, Ki>51,250±20,056 nM, n=4; PDE11, Ki>80,000 nM) and no other significant activity at ~60 other receptors/enzymes. In HEK whole cells expressing rhesus PDE9A2, PF-04447943 inhibits ANP (0.3 μM) stimulated cGMP with an IC50 of 375±36.9 nM (n=16)[2].

In Vivo

Based on i.v. and p.o. dosing, pharmacokinetic studies with PF-04447943 in the rat indicates a Tmax of 0.3 h, T1/2 of 4.9 h, Cl of 21.7 mL/min/kg and an oral bioavailability of 47%. Thirty minutes following oral administration in rats (1-30 mg/kg), PF-04447943 concentrations dose-dependently increase in blood, brain and cerebrospinal fluid (CSF). The brain:plasma exposure ratios 30 min after dosing range from 0.13 at the 1 mg/kg dose to 0.33 at the 30 mg/kg dose. CSF levels are approximately 50% of brain levels. In mice, PF-04447943 (3, 10, 30 mg/kg p.o.) dose-dependently increases plasma and brain concentrations of PF-04447943 while the brain to plasma ratio ranged from 0.26 to 0.7 although this is not entirely dose dependent. CSF cGMP levels increase in a dose-dependent manner from a basal level of 3 pmol/mL to 13.3 pmol/mL (3.5-fold) at the 30 mg/kg dose. CSF cGMP levels also increase in a dose-dependent manner from a basal level of 3 pmol/mL in vehicle treated animals to 13.3 pmol/mL (3.5-fold) at the 30 mg/kg dose. CSF cGMP levels are elevated at all doses tested with a maximal effect of 3.5 fold increase above controls at 30 mg/kg[2].

Clinical Trial
NCT Number Sponsor Condition Start Date Phase
NCT01097876 Pfizer Healthy April 2010 Phase 1
NCT00886093 Pfizer Healthy April 2009 Phase 1
NCT00930059 Pfizer Alzheimer's Disease September 2009 Phase 2
NCT02785770 Pfizer Healthy June 2016 Phase 1
NCT00736528 Pfizer Healthy|Elderly August 2008 Phase 1
NCT00988598 Pfizer Alzheimer's Disease October 2009 Phase 1
NCT00959803 Pfizer Healthy August 2009 Phase 1
NCT00832052 Pfizer Healthy|Elderly January 2009 Phase 1
View MoreCollapse
References
Preparing Stock Solutions
Concentration Volume (DMSO) Mass 1 mg 5 mg 10 mg
1 mM 2.5287 mL 12.6435 mL 25.2870 mL
5 mM 0.5057 mL 2.5287 mL 5.0574 mL
10 mM 0.2529 mL 1.2644 mL 2.5287 mL
Kinase Assay
[1]

PDE enzyme assays are carried out. PDE1A-C, PDE2A, PDE3A/B, PDE4A-D, PDE7A/B, PDE8A/B, PDE9A, PDE10A, and PDE11 are generated from full-length recombinant clones. PDE5 is isolated from human platelets, and PDE6 is isolated from bovine retina. PDE activity is measured by using a scintillation proximity assay (SPA). The effects of PDE inhibitors are investigated by assaying a fixed amount of enzyme and varying inhibitor concentrations in the presence of substrate concentrations of 1/3 Km values for each enzyme, so that the IC50 value approximates the Ki value. PF-4447943 is dissolved in 100% DMSO and diluted to the required concentrations in 15% DMSO water. The enzyme stocks are all thawed slowly and diluted in assay buffer containing 50 mM Tris-HCl (pH 7.5 at room temperature) and 1.3 mM MgCl2. In addition, the PDE1 assay buffers contain 2.8 mM CaCl2. The PDE1C assay also requires the addition of the activator calmodulin at a final assay concentration of 100 units/mL. Incubations are initiated by the addition of diluted enzyme to 384-well plates containing test drugs and radioligand (50 nM [3H]cGMP for PDE1, PDE2, PDE5, PDE6, PDE9, PDE10, and PDE11 and 20 nM [3H]cAMP for PDE3, PDE4, PDE7, and PDE8). The assays are incubated for 30 min at room temperature (60 min for PDE5 and PDE6). The reactions are stopped by the addition of phosphodiesterase SPA beads at a final assay concentration of 0.2 mg/well. PDE9 requires the extra addition of a high concentration (10 μM) of a potent PDE9 inhibitor before beads to stop the reaction completely. Activities of test compounds are assessed by measuring the amount of [3H]5′-GMP or [3H]5′-AMP produced from [3H]cGMP or [3H]cAMP radioligand, respectively. Levels of [3H]5′-GMP or [3H]5′-AMP binds to SPA beads are determined by paralux counting of the assay plates in a Microbeta Trilux Counter 10 h after bead addition. Nonspecific binding is determined by radioligand binding in the presence of a saturating concentration of a potent PDE inhibitor. The IC50 value of each test compound (concentration at which 50% inhibition of specific binding occurs) is calculated by nonlinear regression (curve fitting) of the concentration response[1].

Cell Assay
[2]

PF-04447943 is dissolved in DMSO and stored, and then diluted with appropriate media before use[2].

The rhesus PDE9A2 construct is subcloned into a pcDNA3.3 TOPO vector and HEK 293 cells, stably transfected to constitutively express rhesus PDE9A2 and hNPR1, are incubated with PF-04447943 (30 μM to 1.5 nM) in assay media at a density of 10,000 cells/well, for 30 min at 37°C. Cyclic GMP formation is stimulated by incubation with 0.3 μM ANP (Atrial Natriuretic Peptide) for another 30 min at 37°C. Following incubation, cells are lysed with Antibody/Lysis buffer and ED Reagent for 1 h at room temperature. After a subsequent incubation with EA Reagent for 30 min at room temperature, followed by incubation with Substrate Reagent for 1 h at room temperature, cGMP concentrations are determined by measuring luminescence on the Envision Microplate Luminometer. The maximal inhibition (100% activity) in the cell based assay is determined using 30 μM PF-04447943 and 0% activity is defined by the DMSO control. PF-04447943 is titrated in quadruplicate, in a 10 point titration. Percentage inhibition is calculated using the maximal inhibition value and IC50 values are calculated from concentration response curves using Prism software[2].

Animal Administration
[2]

PF-04447943 is formulated in 20% hydroxypropyl-β-cyclodextrin[2].

Mice and Rat[2]
For the mouse studies, male C57Bl/6J mice are administered PF-04447943 (3, 10, 30 mg/kg p.o.). For the rat studies rats (strain, weight range and supplier as described in the novel object recognition study below) are administered PF-04447943 10 mg/kg i.v. and p.o. At various times after administration the animals are anesthetized with isoflurane; blood samples are withdrawn via cardiac puncture and placed in EDTA tubes on ice. Plasma is separated and frozen at −70°C until assayed for drug concentration. The animals are decapitated, the brain is removed, then homogenized in 3 mL of water per gram of tissue and centrifuged for 15 min at 13,500 g. Sample analysis is conducted using an Acquity UPLC system coupled with a SCIEX API4000 Q-Trap mass spectrometer. Two μL of the sample extract is analyzed using an Acquity UPLC®BEH C18 column (1.7 μm particle size, 50×2.1 mm I.D.) operated at 60°C. The flow rate is 0.7 mL/min. A gradient mobile phase consisting of solvent A (20/80 Methanol/Water, 10 mM Ammonium Acetate) and solvent B (10 mM Ammonium Acetate in Methanol with 0.6 mL/L 10% acetic Acid) is used. The total run time for each sample is 1.2 min. PF-04447943 and the internal standard eluted at 0.61 and 0.67 min, respectively. PF-04447943 and the internal standard are monitored in the positive ion mode at the transition from m/z 396.2 to 203.1 and m/z 477.3 to 266.2, respectively. Quantification is performed using Analyst 1.4 based on duplicate standard curves.

References
M.Wt

395.46

Formula

C₂₀H₂₅N₇O₂

CAS No.

1082744-20-4

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

DMSO: ≥ 54.6 mg/mL

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number

 

Organization name *

Country *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
PF-04447943
Cat. No.:
HY-15441
Quantity: